Categories Covered:PrEP (HIV Pre-Exposure Prophylaxis), HIV Prevention Methods, Emtricitabine/Tenofovir Alafenamide (Descovy), Adverse Events, Comorbidities, and HIV, FDA-Approved HIV Medications, HIV Treatments in Development, HIV Education and Risk Management, HIV Treatment Strategies, Pediatric HIV Care, Pregnancy, Childbirth, and HIV, Dolutegravir (Tivicay), HIV Policy and Advocacy, Rilpivirine (Edurant), HIV Epidemiology, HIV Basic Science and Pathogenesis, Maraviroc (Selzentry, Celsentri), Providing Quality HIV Care, Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), Raltegravir (Isentress)
Two new monoclonal antibodies demonstrated success in helping people living with HIV suppress their viral loads to undetectable levels.
At the recent IDWeek 2016 conference in New Orleans, researchers presented data to try and answer the question: What's causing the rising STI rates among gay and bisexual men over the past several years?
An antiretroviral regimen consisting of just two drugs -- dolutegravir and lamivudine -- led to sustained viral suppression for most people starting HIV treatment for the first time, according to findings from a small study presented in a late-breake...
The FDA has approved Descovy, Gilead Sciences' latest combination pill containing emtricitabine and an updated version of tenofovir.
"Current CDC guidelines may miss a significant number of asymptomatic STIs among PrEP users," researchers concluded, suggesting that STI screening may be warranted at each three-monthly visit.
"There is probably no population that is both more heavily impacted [by HIV] and less discussed around the world than transgender people," said Susan Buchbinder, M.D., during a CROI 2016 presentation.
Research presented at CROI 2016 shows that Truvada PrEP is safe for most people, but impaired kidney function -- usually mild or moderate -- may occur in a small proportion of people on PrEP, especially if they have other risk factors.
While new HIV prevention methods got the most attention at this year’s conference, researchers also presented studies of new drugs for HIV therapy. Two of these are being tested for both treatment and PrEP.
Many HIV studies miscategorize transgender women as men who have sex with men, and there is little research on HIV in trans men. New data confirm very high rates of HIV in trans women -- and also find much more, Liz Highleyman reports.